TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

BACKGROUND: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has anti-apoptotic functions, which may protect TIMP-1 positive cancer cells from the effects of chemotherapy such as docetaxel and gemcitabine. The purpose of the present study was to evaluate TIMP-1 immunoreactivity as a prognostic and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Charlotte Levin Tykjær, Bjerre, Christina, Ejlertsen, Bent, Bjerre, Karsten D, Balslev, Eva, Bartels, Annette, Brünner, Nils, Nielsen, Dorte L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091674/
https://www.ncbi.nlm.nih.gov/pubmed/24884504
http://dx.doi.org/10.1186/1471-2407-14-360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091674/
https://www.ncbi.nlm.nih.gov/pubmed/24884504
http://dx.doi.org/10.1186/1471-2407-14-360

Ejemplares similares